| Roche Pharma (Schweiz) AG - Ocrevus, Konzentrat zur Herstellung einer Infusionslösung |
| 66185 | | 01 | | Ocrevus | | Konzentrat zur Herstellung einer Infusionslösung | | L04AA36 | | Ocrelizumab | | 20.09.2017 | | |
|
| Composition |
| ocrelizumabum 300 mg, natrii acetas trihydricus, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 3.6 mg. |
| Packungsbestandteile |
| Concentrate for infusion | | | | | | | | Active Agent | Dose |
|---|
| Ocrelizumabum | 300mg / 10ml |
| | BAG: Active Agent | Dose |
|---|
| Ocrelizumabum | 300 mg |
| | | | Inactive agents |
|---|
| Acidum Aceticum Glaciale | | Natrii Acetas Trihydricus | | Polysorbatum 20 | | Trehalosum Dihydricum |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 4632.46 | 5054.50 | A | SL | No |
|
